66 related articles for article (PubMed ID: 24470973)
1. Correction: Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
Oncogene; 2024 Apr; ():. PubMed ID: 38678124
[No Abstract] [Full Text] [Related]
2. The Role of Granulocyte-Macrophage Colony-Stimulating Factor in Murine Models of Multiple Sclerosis.
Monaghan KL; Wan ECK
Cells; 2020 Mar; 9(3):. PubMed ID: 32143326
[TBL] [Abstract][Full Text] [Related]
3. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
5. JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition.
Yeh JE; Toniolo PA; Frank DA
JAKSTAT; 2013 Oct; 2(4):e24635. PubMed ID: 24470973
[TBL] [Abstract][Full Text] [Related]
6. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.
Britschgi A; Andraos R; Brinkhaus H; Klebba I; Romanet V; Müller U; Murakami M; Radimerski T; Bentires-Alj M
Cancer Cell; 2012 Dec; 22(6):796-811. PubMed ID: 23238015
[TBL] [Abstract][Full Text] [Related]
7. Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops.
von Manstein V; Yang CM; Richter D; Delis N; Vafaizadeh V; Groner B
Curr Signal Transduct Ther; 2013 Dec; 8(3):193-202. PubMed ID: 25045345
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer.
Lee HS; Lee S; Cho KH
Int J Cancer; 2020 Nov; 147(10):2824-2837. PubMed ID: 32599680
[TBL] [Abstract][Full Text] [Related]
9. Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?
Britschgi A; Radimerski T; Bentires-Alj M
Drug Resist Updat; 2013; 16(3-5):68-72. PubMed ID: 24169539
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
[TBL] [Abstract][Full Text] [Related]
11. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
12. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
Sansone P; Bromberg J
J Clin Oncol; 2012 Mar; 30(9):1005-14. PubMed ID: 22355058
[TBL] [Abstract][Full Text] [Related]
13. Stat5 assumes distinct functions in mammary gland development and mammary tumor formation.
Vafaizadeh V; Klemmt PA; Groner B
Front Biosci (Landmark Ed); 2012 Jan; 17(4):1232-50. PubMed ID: 22201800
[TBL] [Abstract][Full Text] [Related]
14. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.
Marotta LL; Almendro V; Marusyk A; Shipitsin M; Schemme J; Walker SR; Bloushtain-Qimron N; Kim JJ; Choudhury SA; Maruyama R; Wu Z; Gönen M; Mulvey LA; Bessarabova MO; Huh SJ; Silver SJ; Kim SY; Park SY; Lee HE; Anderson KS; Richardson AL; Nikolskaya T; Nikolsky Y; Liu XS; Root DE; Hahn WC; Frank DA; Polyak K
J Clin Invest; 2011 Jul; 121(7):2723-35. PubMed ID: 21633165
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
